Evofem Biosciences
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | - | <1m | 8.2m | 16.8m | 18.2m | 125m | 193m |
% growth | - | - | 1748 % | 104 % | 8 % | 585 % | 55 % |
EBITDA | (45.0m) | (66.9m) | (133m) | (93.6m) | (89.5m) | - | - |
% EBITDA margin | - | (14990 %) | (1615 %) | (556 %) | (491 %) | - | - |
Profit | (80.0m) | (142m) | (205m) | (76.7m) | 53.0m | - | - |
% profit margin | - | (31908 %) | (2489 %) | (456 %) | 291 % | - | - |
EV / revenue | - | 522.2x | 20.5x | 4.5x | 2.5x | - | - |
EV / EBITDA | -5.9x | -3.5x | -1.3x | -0.8x | -0.5x | - | - |
R&D budget | 22.2m | 17.1m | 33.1m | 25.0m | 2.9m | - | - |
R&D % of revenue | - | 3823 % | 402 % | 149 % | 16 % | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $25.0m | Early VC | |
$20.6m | Series C | ||
$6.7m | Series C | ||
N/A | $8.0m | Series C | |
N/A | N/A | IPO | |
N/A | $20.0m | Early VC | |
$25.0m | Series D | ||
N/A | $7.5m | Early VC | |
$80.0m | Post IPO Equity | ||
* | N/A | $100m | Post IPO Equity |
$25.0m | Post IPO Convertible | ||
* | N/A | $26.6m | Post IPO Equity |
* | N/A | $1.4m | Post IPO Debt |
* | $100m Valuation: $100m 5.9x EV/LTM Revenues -1.1x EV/LTM EBITDA | Acquisition | |
Total Funding | AUD174m |
Recent News about Evofem Biosciences
EditEvofem Biosciences is a pioneering company in the sexual and reproductive healthcare sector, focusing on innovative, hormone-free contraceptive solutions. The company primarily serves women in the United States who are seeking non-hormonal, localized methods of birth control. Evofem operates in the pharmaceutical and healthcare markets, leveraging its extensive industry experience to introduce groundbreaking products that align with the growing trend towards natural and organic solutions. The business model revolves around the development, marketing, and sale of its flagship product, Phexxi, a hormone-free contraceptive gel. Revenue is generated through product sales, partnerships, and potentially through licensing agreements. Evofem's leadership team brings over 85 years of combined experience in healthcare and pharmaceuticals, ensuring robust strategic direction and execution. The company aims to empower women by providing them with more natural and effective contraceptive options, thereby addressing a significant gap in the market.
Keywords: hormone-free, contraceptive, women's health, pharmaceutical, Phexxi, non-hormonal, reproductive healthcare, innovation, natural products, U.S. market.